Capital Research Global Investors Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Capital Research Global Investors lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,222,840 shares of the biopharmaceutical company’s stock after buying an additional 31,184 shares during the quarter. Capital Research Global Investors owned approximately 5.47% of Alnylam Pharmaceuticals worth $3,293,516,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in ALNY. Thematics Asset Management bought a new position in Alnylam Pharmaceuticals during the second quarter valued at $1,995,000. Mediolanum International Funds Ltd purchased a new stake in Alnylam Pharmaceuticals during the third quarter valued at approximately $11,389,000. Rakuten Investment Management Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $14,205,000. Generali Asset Management SPA SGR boosted its holdings in shares of Alnylam Pharmaceuticals by 6,368.0% in the 3rd quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock worth $1,475,000 after purchasing an additional 3,184 shares during the period. Finally, Investment Management Corp of Ontario increased its position in shares of Alnylam Pharmaceuticals by 35.4% during the 2nd quarter. Investment Management Corp of Ontario now owns 31,521 shares of the biopharmaceutical company’s stock valued at $10,279,000 after purchasing an additional 8,244 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ALNY shares. Oppenheimer assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $510.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 18th. Royal Bank Of Canada decreased their price objective on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a report on Tuesday, January 20th. Needham & Company LLC reduced their price objective on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. Finally, Bank of America reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $477.96.

Insider Activity

In other news, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $319.73, for a total value of $528,193.96. Following the sale, the executive vice president directly owned 21,860 shares of the company’s stock, valued at $6,989,297.80. This represents a 7.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Tolga Tanguler sold 1,598 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $523,584.70. Following the completion of the sale, the executive vice president owned 36,606 shares in the company, valued at $11,993,955.90. The trade was a 4.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 53,923 shares of company stock valued at $18,072,087. 1.20% of the stock is owned by insiders.

Alnylam Pharmaceuticals Trading Up 0.9%

NASDAQ ALNY opened at $323.53 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55. The company has a fifty day simple moving average of $350.74 and a two-hundred day simple moving average of $413.17. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The stock has a market cap of $42.91 billion, a P/E ratio of 189.20 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The firm had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same period in the previous year, the company earned ($0.65) earnings per share. Alnylam Pharmaceuticals’s revenue was up 84.9% on a year-over-year basis. On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.